EGFR and adenocarcinoma: Although targeted therapy against adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutation or anaplastic lymphoma kinase (ALK) and ROS1 proto-oncogene receptor tyrosine kinase (ROS1) rearrangements have shown dramatic effects [11–13], few targeted therapies against SCC have been identified.